The Aftermath of Hepatitis C Drugs on Specialty Spending

2016-01-11 15:35:00
Tags: daclatasvir,Gilead,Harvoni,HCV,hepatitis C,hepatitis C drug cost,hepatitis C life expectancy,interferon,ribavirin,signs of hepatitis C,sofosbuvir,Sovaldi,specialty pharmacy,symptoms of hepatitis C,Viekira Pak,specialty pharmacy

David Lassen, chief clinical officer at Prime Therapeutics, discusses how high cost hepatitis C drugs have impacted the entire specialty landscape.



 

Related Content
Hepatitis C Drug Spending Continues to Skyrocket
Keeping Up With Advances in Hepatitis C Treatment
The True Meaning of a Hepatitis C Cure
Can Direct-Acting Antiviral Drugs Cure Hepatitis C in 6 Weeks?